Literature DB >> 16711756

Quantitative structure-activity relationship studies on inhibition of HERG potassium channels.

Katsumi Yoshida1, Tomoko Niwa.   

Abstract

The human ether-a-go-go-related gene (HERG) protein forms the ion channel responsible for the rapidly acting delayed rectifier potassium current, I(Kr), and its blockade is a significant contributor to prolongation of the QT interval. Using descriptors which have clear physicochemical meanings and are familiar to medicinal chemists, we have carried out 2D-quantitative structure-activity relationship (2D-QSAR) studies on 104 HERG channel blockers with diverse structures collected from the literature, and we have formulated interpretable models to guide chemical-modification studies and virtual screening. Statistically significant descriptors were selected by a genetic algorithm, and the final model included the octanol/water partition coefficient, topological polar surface area, diameter, summed surface area of atoms with partial charges from -0.25 to -0.20, and an indicator variable representing the experimental conditions. The statistics were r = 0.839, r2 = 0.704, q2 = 0.671, s = 0.763, and F = 46.6. The correspondence of the molecular determinants derived from the 2D-QSAR models with the 3D structural characteristics of the putative binding site in a homology-modeled HERG channel is also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16711756     DOI: 10.1021/ci050450g

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  8 in total

1.  Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.

Authors:  Li-li Liu; Jing Lu; Yin Lu; Ming-yue Zheng; Xiao-min Luo; Wei-liang Zhu; Hua-liang Jiang; Kai-xian Chen
Journal:  Acta Pharmacol Sin       Date:  2014-06-30       Impact factor: 6.150

2.  Rank order entropy: why one metric is not enough.

Authors:  Margaret R McLellan; M Dominic Ryan; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2011-08-29       Impact factor: 4.956

3.  A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.

Authors:  Lei Du-Cuny; Lu Chen; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-10-13       Impact factor: 4.956

4.  In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation.

Authors:  Madhukumar Venkatesh; Hongwei Wang; Julie Cayer; Melissa Leroux; Dany Salvail; Bhaskar Das; Jay E Wrobel; Sridhar Mani
Journal:  Mol Pharmacol       Date:  2011-04-04       Impact factor: 4.436

5.  Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.

Authors:  Rima Hajjo; Christopher M Grulke; Alexander Golbraikh; Vincent Setola; Xi-Ping Huang; Bryan L Roth; Alexander Tropsha
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

6.  Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.

Authors:  Gilbert M Rishton; Gary C Look; Zhi-Jie Ni; Jason Zhang; Yingcai Wang; Yaodong Huang; Xiaodong Wu; Nicholas J Izzo; Kelsie M LaBarbera; Colleen S Limegrover; Courtney Rehak; Raymond Yurko; Susan M Catalano
Journal:  ACS Med Chem Lett       Date:  2021-08-09       Impact factor: 4.632

7.  Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities.

Authors:  Saba Munawar; Monique J Windley; Edwin G Tse; Matthew H Todd; Adam P Hill; Jamie I Vandenberg; Ishrat Jabeen
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

8.  Capsule Networks Showed Excellent Performance in the Classification of hERG Blockers/Nonblockers.

Authors:  Yiwei Wang; Lei Huang; Siwen Jiang; Yifei Wang; Jun Zou; Hongguang Fu; Shengyong Yang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.